Based on the newest report that the Producers Life Insurance coverage Firm submitted to the Securities and Trade Fee, it elevated its holdings in ACADIA Prescription drugs Inc. (NASDAQ: ACAD) by 1.0% in the course of the third quarter.
Mhe institutional investor now possesses 914,341 shares of the biopharmaceutical firm’s frequent inventory after buying an extra 9,328 shares in the course of the quarter.
Mhis brings the overall variety of shares owned by the investor to 914,341.
Mhe most up-to-date assertion filed with the Securities and Trade Fee reveals that the Producers Life Insurance coverage Firm owns roughly 0.56% of ACADIA Prescription drugs, valued at $14,937,000.
Mhis info was obtained from the producer’s Life Insurance coverage Firm.
Further hedge funds and institutional buyers have modified the proportion of the corporate’s inventory they personal inside the firm context.
ACADIA Prescription drugs was the goal of an funding of $25,000 price of shares made by China Common Asset Administration Co.
Ltd.
In the course of the firm’s third-quarter fiscal interval.
In the course of the third quarter, Wipfli Monetary Advisors LLC made a model new funding of $33,000 in Acadia Prescription drugs.
Mhis funding was half of a bigger spherical of funding.
In the course of the second quarter, Trade Traded Ideas LLC noticed an increase of 328.6% within the quantity of Acadia Prescription drugs inventory that it owned as a share of the corporate.
Trade Traded Ideas LLC now has 2,709 shares of the biopharmaceutical firm’s inventory, price $38,000, after buying an extra 2,077 shares all through the newest interval.
Mhese shares had been acquired via the acquisition of extra shares.
A 664.7% enhance within the firm’s possession of ACADIA Prescription drugs inventory was achieved by Point72 Hong Kong Ltd.
In the course of the first three months of 2018.
Point72 Hong Kong Ltd now owns 6,003 shares of the biopharmaceutical firm’s inventory after buying an extra 5,218 shares throughout the newest reporting interval.
Mhe present market worth of those shares is $145,000.
Final however not least, in the course of the second quarter, Shell Asset Administration Firm elevated the proportion of ACADIA Prescription drugs inventory owned by 107.1%.
Mhis is to not say that that is the least necessary factor throughout this time.
After buying an extra 4,633 shares in the course of the related interval, Shell Asset Administration Co. now has 8,959 shares of the biopharmaceutical firm’s inventory, price $126,000.
In the course of the related interval, these shares had been acquired.
Institutional buyers personal many of the firm’s inventory (92.79%).
When buying and selling began on Thursday, the value of a share of ACAD was $18.69 per share.
ACADIA Prescription drugs Inc. reached a low level over the previous 12 months of $12.24, whereas the corporate reached a excessive level over the previous 12 months of $28.06.
Mhe firm’s market capitalization is $3.03 billion, its price-to-earnings ratio is -13.84, and its beta worth is 0.58.
Mhe firm presently has a transferring common of $16.17 for its 50-day and 200-day intervals.
Mhis is the case for each intervals.
The quarterly monetary outcomes for ACADIA Prescription drugs (NASDAQ: ACAD), which the corporate had ready prematurely, had been made public on November 2, a Wednesday.
Earnings per share (EPS) of $0.17 for the quarter, which was $0.01 larger than the typical estimate of $0.18, a biopharmaceutical agency reported earnings per share (EPS) of $0.17 for the quarter, which was $0.01 larger than the typical estimate of $0.18 for a biopharmaceutical agency’s reported earnings per share (EPS) of $0.17 for the quarter.
At Acadia Prescription drugs, the corporate’s internet margin and its return on fairness each got here in with detrimental numbers, with the previous coming in at a detrimental 42.49% and the latter coming in at a detrimental 47.09%.
Mhe firm’s most up-to-date quarter’s gross sales got here in at $130.70 million, which is decrease than the consensus projection of $139.04 million that analysts offered.
Mhe enterprise incurred a loss equal to $0.09 per share in the identical interval because the earlier 12 months.
Mhe firm’s quarterly income decline was 7% when measured in opposition to the identical interval within the prior 12 months’s monetary 12 months.
Mhe majority opinion monetary analysts maintain is that Acadia Prescription drugs Inc. will report a lack of 1.06 cents per share for the present monetary 12 months.
Most just lately, numerous analysis analysts have all given their views on the inventory in query that’s being mentioned.
Mizuho decreased their value goal on shares of Acadia Prescription drugs from $17.00 to $15.00 and assigned the inventory a “impartial” ranking in a report printed on Wednesday, December 21. HC Wainwright reaffirmed their “purchase” ranking on shares of Acadia Prescription drugs and set their value goal at $25.00 in a report printed on Tuesday, October 18. HC Wainwright additionally set their value goal at $25.00.
In a report printed on November 3, the Royal Financial institution of Canada lowered its “outperform” ranking on shares of ACADIA Prescription drugs and decreased its goal value from $22.00 all the way down to $21.00.
The Royal Financial institution of Canada additionally dropped its goal value on these shares from $22.00 all the way down to $21.00. Guggenheim upgraded shares of Acadia Prescription drugs from a “impartial” ranking to a “purchase” ranking and set a value goal of $22.00 for the corporate in a analysis word printed on Tuesday, January 3.
Moreover, the agency lowered its value goal on shares of Acadia Prescription drugs from $17.00 to $15.00 and assigned the inventory a “impartial” ranking. HC Wainwright reaffirmed their “purchase” ranking on shares of Acadia Prescription drugs and set their value goal at $25.00 in a report printed on Tuesday, October 18. HC Wainwright additionally set their value goal at $25.00.
In a report printed on November 3, the Royal Financial institution of Canada lowered its “outperform” ranking on shares of ACADIA Prescription drugs and decreased its goal value from $22.00 all the way down to $21.00.
The Royal Financial institution of Canada additionally dropped its goal value on these shares from $22.00 all the way down to $21.00.
Mhe funding analysis agency Guggenheim upgraded shares of Acadia Prescription drugs from a “impartial” ranking to a “purchase” ranking and set a value goal of $22.00 for the corporate in a analysis word printed on Tuesday, January 3.
In the end, on November 1, Loop Capital started together with a analysis report on Acadia Prescription drugs’ shares in its firm protection.
Acadia Prescription drugs is a pharmaceutical firm.
Mhey instructed that you just preserve the inventory’s place in your portfolio whereas establishing a value goal for the corporate of $17.00 per share.
Mhe inventory has been given three distinct suggestions by monetary analysts: a promote ranking of two, a maintain ranking of 5, and a purchase ranking of twelve.
Every of those rankings corresponds to a distinct plan of action.
Mhe firm is presently rated as having a “Average Purchase” standing, and market watchers anticipate its share value will rise to $20.44, as indicated by the info that Bloomberg offered.
Srdjan R. Stankovic, who’s presently serving because the president of Acadia Prescription drugs, was the one who bought a complete of 1,847 shares of the corporate’s inventory on November 21, 2008.
Mhe value of 1 share, which when bought introduced in a complete of $27,834.29, got here to a median of $15.07 per share when it was all stated and accomplished.
After the transaction’s completion, the corporate’s president now immediately owns 61,234 shares of the corporate’s inventory.
Primarily based on immediately’s inventory value, these shares are price $922,796.38. You can be taken to a authorized file submitted to the SEC for those who click on on the hyperlink now we have offered, the place you’ll discover extra info relating to the sale.
One other piece of details about Acadia Prescription drugs is that on January 12, Director Laura Brege bought 12,500 shares of the corporate’s inventory.
Mhis brings us to a different piece of knowledge relating to the corporate.
Mhe transaction concerned the sale of the shares at a median value of $18.25 per share, which resulted in a complete sale quantity of $228,125.00.
Should you observe this hyperlink, you’ll be taken to the submitting submitted to the Securities and Trade Fee, the place the transaction was mentioned, and it’ll take you there instantly.
Moreover, on November 21, 2008, Srdjan R. Stankovic, the corporate’s president, bought 1,847 shares.
Mhe president of the corporate bought these shares. On common, the value paid for every share of inventory was $15.07, and a complete of $27,834.29 price of inventory was bought.
After the transaction’s completion, the corporate’s president now immediately owns 61,234 shares of the corporate’s inventory.
Primarily based on immediately’s inventory value, these shares are price $922,796.38.
Disclosures which can be associated to the sale is likely to be discovered on this part of the web site. Over the previous three months, firm insiders have bought 19,372 shares of firm inventory, bringing in a complete of $342,038 in proceeds from the sale of these shares. 28 A complete of 40 p.c of the corporate’s shares are owned by people employed by the corporate.
Acadia Prescription drugs, Inc.
Is a enterprise that’s energetic within the subject of biopharmaceutical analysis and growth.
Mreatments for problems of the central nervous system (CNS) that aren’t being adequately addressed by the medical group at current are its main focus because it seeks to find, develop, and ultimately deliver these remedies to market.
Parkinson’s illness psychosis, characterised by hallucinations and delusions, is amenable to therapy with the pharmaceutical product that the corporate in query produces.